Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit

Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce inhibitor risk in nonsevere hemophilia, we evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Haowei (Linda), Chan, Stella, Yenson, Paul, Jackson, Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714690/
https://www.ncbi.nlm.nih.gov/pubmed/29108420
http://dx.doi.org/10.1177/1076029617737836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714690/
https://www.ncbi.nlm.nih.gov/pubmed/29108420
http://dx.doi.org/10.1177/1076029617737836

Ejemplares similares